Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fredrik Öhrn

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Pharmaceutical Statistics|December 18, 2025
Robust Modestly Weighted Log-Rank TestsDominic Magirr, Fredrik Öhrn
Journal of Biopharmaceutical Statistics|October 23, 2021
Improved group sequential Holm procedures for testing multiple correlated hypotheses over timeFredrik Öhrn, Julia Niewczas, Carl-Fredrik Burman
Biometrics|June 17, 2026
Practical considerations when using the covariate-adjusted log-rank test for the analysis of time-to-event endpoints in oncology trialsDaniel Backenroth, Sanne Roels, Shiva Dibaj, et al.
Journal of Biopharmaceutical Statistics|March 12, 2021
Statistical and practical considerations in designing of immuno-oncology trialsPralay Mukhopadhyay, Wenmei Huang, Paul Metcalfe, et al.
Journal of Clinical Pharmacology|June 5, 2014
Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinibEmma Boström, Fredrik Öhrn, Eva Hanze, et al.
Journal of the American College of Cardiology|October 19, 2019
Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials: JACC Review Topic of the WeekJohn Gregson, Linda Sharples, Gregg W Stone, et al.
BMC Infectious Diseases|November 11, 2019
Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm CountyCaroline Gahrton, Gabriel Westman, Karin Lindahl, et al.
European Journal of Heart Failure|May 29, 2021
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trialScott D Solomon, Rudolf A de Boer, David DeMets, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|December 18, 2025
Robust Modestly Weighted Log-Rank TestsDominic Magirr, Fredrik Öhrn
Journal of Biopharmaceutical Statistics|October 23, 2021
Improved group sequential Holm procedures for testing multiple correlated hypotheses over timeFredrik Öhrn, Julia Niewczas, Carl-Fredrik Burman
Biometrics|June 17, 2026
Practical considerations when using the covariate-adjusted log-rank test for the analysis of time-to-event endpoints in oncology trialsDaniel Backenroth, Sanne Roels, Shiva Dibaj, et al.
Journal of Biopharmaceutical Statistics|March 12, 2021
Statistical and practical considerations in designing of immuno-oncology trialsPralay Mukhopadhyay, Wenmei Huang, Paul Metcalfe, et al.
Journal of Clinical Pharmacology|June 5, 2014
Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinibEmma Boström, Fredrik Öhrn, Eva Hanze, et al.
Journal of the American College of Cardiology|October 19, 2019
Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials: JACC Review Topic of the WeekJohn Gregson, Linda Sharples, Gregg W Stone, et al.
BMC Infectious Diseases|November 11, 2019
Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm CountyCaroline Gahrton, Gabriel Westman, Karin Lindahl, et al.
European Journal of Heart Failure|May 29, 2021
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trialScott D Solomon, Rudolf A de Boer, David DeMets, et al.
Pageof 1